SCHEMBL6462282

SCHEMBL6462282

NC(CCC(O)c1nc2ccccc2o1)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.38
RAB9A P51151 3/20 0.38
MAPT P10636 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.38
BCHE P06276 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
TP53 P04637 2/20 0.36
LMNA P02545 1/20 0.36
DDAH1 O94760 1/20 0.35
ADRA2C P18825 1/20 0.35
XDH P47989 1/20 0.35
ALDH1A1 P00352 2/20 0.35
PTPN2 P17706 2/20 0.35
GAA P10253 1/20 0.35
PKM P14618 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HPGD P15428 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24928637 0.78 LOXL2 (0.47) NPC1RAB9AMAPTLOXL2BCHE
Hydrochloric Acid SCHEMBL3621160 0.78 LOXL2 (0.47) NPC1RAB9AMAPTLOXL2BCHE
SCHEMBL14562892 0.78 HSF1 (0.44) NPC1RAB9AMAPTLOXL2SMN1; SMN2
SCHEMBL6468700 0.77 LOXL2 (0.49) NPC1RAB9AMAPTLOXL2BCHE
SCHEMBL6206770 0.77 MAPT (0.48) NPC1RAB9AMAPTSMN1; SMN2TP53
SCHEMBL5703678 0.76 HDAC3 (0.50) NPC1RAB9AMAPTLOXL2SMN1; SMN2
SCHEMBL6207598 0.76 HDAC3 (0.50) NPC1RAB9AMAPTLOXL2SMN1; SMN2
SCHEMBL6630971 0.76 HDAC3 (0.47) NPC1RAB9AMAPTLOXL2TP53
SCHEMBL4004973 0.76 HPGD (0.44) NPC1RAB9AMAPTBCHESMN1; SMN2
Hydrochloric Acid SCHEMBL7255759 0.75 HDAC3 (0.49) NPC1RAB9AMAPTLOXL2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1516877-A1 Amine derivatives as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-03-23 EP disclosed
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-12-18 US disclosed
US-6576630-B1 Alkanoyl substituted benzooxazoles or naphthooxazoles AXYS PHARMACEUTICALS, INC. 2003-06-10 US disclosed
EP-1161422-A1 AMINE DERIVATIVES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-12-12 EP disclosed
WO-2000055144-A1 AMINE DERIVATIVES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors SERPINB1, CTRL, CTSZ NPC1 428/4885RAB9A 1895/4885MAPT 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.